<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04910178</url>
  </required_header>
  <id_info>
    <org_study_id>BeniSuef</org_study_id>
    <nct_id>NCT04910178</nct_id>
  </id_info>
  <brief_title>Follow-up of NAFLD Patients With MRI-PDFF</brief_title>
  <official_title>Evaluating the Effect of Pentoxifylline, Ursodiol, and Empagliflozin on Fatty Liver of Patients With Type-2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asmaa Abdelfattah Elsayed</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beni-Suef University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The liver is a key organ in metabolism and contributes to T2DM development and insulin&#xD;
      resistance via unclear mechanisms that may involve liver fat accumulation, inflammatory&#xD;
      signals, and immune cells are proposed to play an important role in the pathogenesis of both&#xD;
      NAFLD and T2DM.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to define&#xD;
&#xD;
        -  The effects of PTX, Empagliflozin as an example of SGLT-2 inhibitors and UDCA on liver&#xD;
           biomarkers and liver steatosis in type 2 diabetic patients.&#xD;
&#xD;
        -  Studying PTX, Empagliflozin as an example of SGLT-2 inhibitors and UDCA efficacy and&#xD;
           safety as add-on therapy in type 2 diabetic patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Only participants did not know which group and treatment they are on.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>liver fat content (percent)</measure>
    <time_frame>6-months</time_frame>
    <description>measured by MRI-PDFF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fatty liver staging (0, I, II, and III)</measure>
    <time_frame>6-months</time_frame>
    <description>using ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Serum Gamma glutamyl transferase (γ-GT)</measure>
    <time_frame>6-months</time_frame>
    <description>IU/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c (%)</measure>
    <time_frame>6-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting and 2-hr post-prandial serum glucose (mg/dl)</measure>
    <time_frame>6-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>6-months</time_frame>
    <description>(serum triglycerides, total cholesterol, LDL, HDL) (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in liver enzymes</measure>
    <time_frame>6-months</time_frame>
    <description>AST (IU/l) and ALT (IU/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in direct and total bilirubin</measure>
    <time_frame>6-months</time_frame>
    <description>(mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in total protein and albumin</measure>
    <time_frame>6-months</time_frame>
    <description>(g/l)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diabetes Type 2</condition>
  <condition>NAFLD</condition>
  <arm_group>
    <arm_group_label>Empa group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will be given Empagliflozin 25 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTX group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will be given PTX 400 mg twice daily or 3 times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UDCA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will be given UDCA 500 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients will be given a placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 25 MG</intervention_name>
    <description>tablets to be taken orally once a day</description>
    <arm_group_label>Empa group</arm_group_label>
    <other_name>Jardiance 25mg tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic acid</intervention_name>
    <description>tablets to be taken orally twice a day</description>
    <arm_group_label>UDCA group</arm_group_label>
    <other_name>Ursofalk tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline 400 MG</intervention_name>
    <description>tablets to be taken orally twice a day</description>
    <arm_group_label>PTX group</arm_group_label>
    <other_name>Trental tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>just starch tablets without any active agents</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who are willing to participate in this study&#xD;
&#xD;
          -  Adults aged ≥ 18 years old presented at the clinic with a confirmed diagnosis of T2DM&#xD;
             who are on sulfonylurea for the last 6 months at least and diagnosed with NAFLD.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Patients who refused to participate in this trial&#xD;
&#xD;
               -  Patients diagnosed with Type 1 diabetes&#xD;
&#xD;
               -  Previous history of alcohol intake&#xD;
&#xD;
               -  history of recurrent attacks of ketoacidosis in a diabetic patient&#xD;
&#xD;
               -  Type 2 diabetic patient with kidney dysfunction (estimated eGFR below&#xD;
                  60ml/min/1.73m2 or CrCl below 60ml/min) or on dialysis&#xD;
&#xD;
               -  Previous history of taking medication that may alter either drug efficacy (eg,&#xD;
                  corticosteroids, oral contraceptives, and thiazide diuretics)&#xD;
&#xD;
               -  Evidence of another liver disease (viral hepatitis, drug-induced liver disease,&#xD;
                  autoimmune hepatitis)&#xD;
&#xD;
               -  Lactating/pregnant female or children ≤ 18&#xD;
&#xD;
               -  Any contraindication for Empagliflozin including:&#xD;
&#xD;
                    1. History of recurrent attacks of UTI or Genital infection in females&#xD;
&#xD;
                    2. History of recurrent foot injuries or infections&#xD;
&#xD;
                    3. Type 2 diabetic patient with CV disease especially NYHA classes III/ IV&#xD;
&#xD;
                    4. Immunocompromised patients or with a history of inflammatory, immunological,&#xD;
                       or malignant diseases.&#xD;
&#xD;
               -  Any contraindication for PTX including:&#xD;
&#xD;
                    1. Hypersensitivity to PTX&#xD;
&#xD;
                    2. Patients with peptic ulcer disease or tendency for bleeding&#xD;
&#xD;
               -  Any contraindication for UDCA including:&#xD;
&#xD;
                    1. Hypersensitivity to UDCA&#xD;
&#xD;
                    2. Patients with biliary disease or hepatobiliary disease (ascites, jaundice)&#xD;
&#xD;
                    3. Patients with hepatic encephalopathy or gallstone pancreatitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Adults aged ≥ 18 years old presented at the clinic with a confirmed diagnosis of T2DM</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asmaa A Elsayed, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BUC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Asmaa A Elsayed, PhD</last_name>
    <phone>01095727201</phone>
    <email>Asmaa_abdelfattah86@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Minya University Hospital</name>
      <address>
        <city>Minya</city>
        <zip>61118</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asmaa A Elsayed, PhD</last_name>
      <phone>01095727201</phone>
      <email>Asmaa_abdelfattah86@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beni-Suef University</investigator_affiliation>
    <investigator_full_name>Asmaa Abdelfattah Elsayed</investigator_full_name>
    <investigator_title>PHD candidate in clinical pharmacy department and PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Pentoxifylline</mesh_term>
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

